Jim Cramer on Veradermics: “It’s Double or Nothing With MANE”

Veradermics, Incorporated (NYSE:MANE) was among the stocks Jim Cramer looked at as he discussed the recent bounce in software stocks. Inquiring about the stock, a caller mentioned that they consider it a spec. In response, Cramer said:

Yeah, it’s alopecia. Okay, here’s the problem with that: never been solved. Always supposed to be right around the corner. It’s a very risky stock. But I have to tell you, if it can be solved, it’s worth double. So it’s double or nothing with MANE.

Image by Sergei Tokmakov, Esq. from Pixabay

Veradermics, Incorporated (NYSE:MANE) is a biopharmaceutical company that develops specialized treatments for skin and hair conditions, such as pattern hair loss and common warts. The company reported its Q4 and FY2025 financial results on March 30.

The company posted a net loss of $21.8 million for Q4 2025. For the full year, Veradermics, Incorporated (NYSE:MANE) reported a net loss of $70 million, compared to $26.5 million in the prior year. As of December 31, the company’s cash, cash equivalents, and marketable securities stood at $141.9 million.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.